2025 Q3 -tulosraportti
81 päivää sitten50 min
2,25 DKK/osake
Viimeisin osinko
1,53%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
266
Myynti
Määrä
410
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 190 | - | - | ||
| 118 | - | - | ||
| 71 | - | - | ||
| 124 | - | - | ||
| 222 | - | - |
Ylin
410,3VWAP
Alin
399,3VaihtoMäärä
62,4 154 002
VWAP
Ylin
410,3Alin
399,3VaihtoMäärä
62,4 154 002
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenIt's a bit difficult to figure out if, after 5 years of price-wise desert wandering, there is hope for a price increase, or if it will continue flat for 5 more years! I don't think any positive gain has materialized from the acquisition of Chr. Hansen, as they otherwise announced. I myself owned Chr. Hansen.
·7 t sittenUnfortunately, I believe that the period of stagnation will continue right up until the earnings report day on 25/2. The stock is in the short sellers' spotlight, and as recently as Friday, the short interest increased by 0.10%, so the total short position now amounts to approx. 3.01%, which corresponds to approx. 14 million shares. At the same time, with a lack of company-specific news, almost invisible analyst coverage and relatively high P/E, there is a lack of appeal to invest in this stock. This gives short sellers good opportunities to push the price down or keep it in check. However, I still hope and believe that the good momentum from Q3 in 2025 with growth in all divisions will continue and be reflected in the annual report on Feb 25. But most interesting, of course, will be the company's forward-looking expectations, where I hope they will announce growth a little less conservatively. Just as a possible share buyback program and a good dividend could also boost the share price upwards.
·18.1.Does anyone know if the new possible tariff from Trump affects novonesis? (The tariff is possibly increased from 15% to 25%) How large is their export to the USA?
·18.1.Novonesis' strategy in the weight loss market, where they position themselves as a subcontractor and technology partner rather than a direct competitor to pharmaceutical giants like Novo Nordisk.: Their strategy is threefold: 1. Partnership with Novo Nordisk (Metabolic Health): They have a research collaboration with Novo Nordisk to develop synbiotics (probiotics + prebiotics) – dietary supplements or medical foods that, via the gut flora, can supplement medical treatment for obesity and influence blood sugar regulation. 2. "Pick-and-Shovel" for the GLP-1 wave (Muscle Preservation): Novonesis supplies enzymes and cultures to the food industry to produce high-protein dairy products. This is to meet the increased need for protein to preserve muscle mass in patients using weight loss medication (GLP-1 medication like Wegovy). 3. Ingredients for calorie and fat reduction: They supply biosolutions (enzymes) to food producers, making it possible to reduce fat content (up to 20% in baked goods with e.g. Optiva® Cookie LO) and sugar content in foods, without compromising taste. Novonesis is considered the "backend" player in the market, supplying ingredients for healthier food and future bacteria-based weight loss solutions.
·9.1.A very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·12.1.After seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.
·12.1.You will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.- ·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
81 päivää sitten50 min
2,25 DKK/osake
Viimeisin osinko
1,53%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenIt's a bit difficult to figure out if, after 5 years of price-wise desert wandering, there is hope for a price increase, or if it will continue flat for 5 more years! I don't think any positive gain has materialized from the acquisition of Chr. Hansen, as they otherwise announced. I myself owned Chr. Hansen.·7 t sittenUnfortunately, I believe that the period of stagnation will continue right up until the earnings report day on 25/2. The stock is in the short sellers' spotlight, and as recently as Friday, the short interest increased by 0.10%, so the total short position now amounts to approx. 3.01%, which corresponds to approx. 14 million shares. At the same time, with a lack of company-specific news, almost invisible analyst coverage and relatively high P/E, there is a lack of appeal to invest in this stock. This gives short sellers good opportunities to push the price down or keep it in check. However, I still hope and believe that the good momentum from Q3 in 2025 with growth in all divisions will continue and be reflected in the annual report on Feb 25. But most interesting, of course, will be the company's forward-looking expectations, where I hope they will announce growth a little less conservatively. Just as a possible share buyback program and a good dividend could also boost the share price upwards.
- ·18.1.Does anyone know if the new possible tariff from Trump affects novonesis? (The tariff is possibly increased from 15% to 25%) How large is their export to the USA?
- ·18.1.Novonesis' strategy in the weight loss market, where they position themselves as a subcontractor and technology partner rather than a direct competitor to pharmaceutical giants like Novo Nordisk.: Their strategy is threefold: 1. Partnership with Novo Nordisk (Metabolic Health): They have a research collaboration with Novo Nordisk to develop synbiotics (probiotics + prebiotics) – dietary supplements or medical foods that, via the gut flora, can supplement medical treatment for obesity and influence blood sugar regulation. 2. "Pick-and-Shovel" for the GLP-1 wave (Muscle Preservation): Novonesis supplies enzymes and cultures to the food industry to produce high-protein dairy products. This is to meet the increased need for protein to preserve muscle mass in patients using weight loss medication (GLP-1 medication like Wegovy). 3. Ingredients for calorie and fat reduction: They supply biosolutions (enzymes) to food producers, making it possible to reduce fat content (up to 20% in baked goods with e.g. Optiva® Cookie LO) and sugar content in foods, without compromising taste. Novonesis is considered the "backend" player in the market, supplying ingredients for healthier food and future bacteria-based weight loss solutions.
- ·9.1.A very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·12.1.After seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.·12.1.You will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.
- ·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
266
Myynti
Määrä
410
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 190 | - | - | ||
| 118 | - | - | ||
| 71 | - | - | ||
| 124 | - | - | ||
| 222 | - | - |
Ylin
410,3VWAP
Alin
399,3VaihtoMäärä
62,4 154 002
VWAP
Ylin
410,3Alin
399,3VaihtoMäärä
62,4 154 002
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
2025 Q3 -tulosraportti
81 päivää sitten50 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
2,25 DKK/osake
Viimeisin osinko
1,53%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenIt's a bit difficult to figure out if, after 5 years of price-wise desert wandering, there is hope for a price increase, or if it will continue flat for 5 more years! I don't think any positive gain has materialized from the acquisition of Chr. Hansen, as they otherwise announced. I myself owned Chr. Hansen.·7 t sittenUnfortunately, I believe that the period of stagnation will continue right up until the earnings report day on 25/2. The stock is in the short sellers' spotlight, and as recently as Friday, the short interest increased by 0.10%, so the total short position now amounts to approx. 3.01%, which corresponds to approx. 14 million shares. At the same time, with a lack of company-specific news, almost invisible analyst coverage and relatively high P/E, there is a lack of appeal to invest in this stock. This gives short sellers good opportunities to push the price down or keep it in check. However, I still hope and believe that the good momentum from Q3 in 2025 with growth in all divisions will continue and be reflected in the annual report on Feb 25. But most interesting, of course, will be the company's forward-looking expectations, where I hope they will announce growth a little less conservatively. Just as a possible share buyback program and a good dividend could also boost the share price upwards.
- ·18.1.Does anyone know if the new possible tariff from Trump affects novonesis? (The tariff is possibly increased from 15% to 25%) How large is their export to the USA?
- ·18.1.Novonesis' strategy in the weight loss market, where they position themselves as a subcontractor and technology partner rather than a direct competitor to pharmaceutical giants like Novo Nordisk.: Their strategy is threefold: 1. Partnership with Novo Nordisk (Metabolic Health): They have a research collaboration with Novo Nordisk to develop synbiotics (probiotics + prebiotics) – dietary supplements or medical foods that, via the gut flora, can supplement medical treatment for obesity and influence blood sugar regulation. 2. "Pick-and-Shovel" for the GLP-1 wave (Muscle Preservation): Novonesis supplies enzymes and cultures to the food industry to produce high-protein dairy products. This is to meet the increased need for protein to preserve muscle mass in patients using weight loss medication (GLP-1 medication like Wegovy). 3. Ingredients for calorie and fat reduction: They supply biosolutions (enzymes) to food producers, making it possible to reduce fat content (up to 20% in baked goods with e.g. Optiva® Cookie LO) and sugar content in foods, without compromising taste. Novonesis is considered the "backend" player in the market, supplying ingredients for healthier food and future bacteria-based weight loss solutions.
- ·9.1.A very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·12.1.After seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.·12.1.You will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.
- ·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
266
Myynti
Määrä
410
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 190 | - | - | ||
| 118 | - | - | ||
| 71 | - | - | ||
| 124 | - | - | ||
| 222 | - | - |
Ylin
410,3VWAP
Alin
399,3VaihtoMäärä
62,4 154 002
VWAP
Ylin
410,3Alin
399,3VaihtoMäärä
62,4 154 002
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 195 425 | 195 425 | 0 | 0 |